- Latest available (Revised)
- Point in Time (25/05/2023)
- Original (As made)
Version Superseded: 06/11/2023
Point in time view as at 25/05/2023. This version of this provision has been superseded.
You are viewing this legislation item as it stood at a particular point in time. A later version of this or provision, including subsequent changes and effects, supersedes this version.
Note the term provision is used to describe a definable element in a piece of legislation that has legislative effect – such as a Part, Chapter or section.
The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013, Section 27 is up to date with all changes known to be in force on or before 05 August 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.
Changes and effects yet to be applied by the editorial team are only applicable when viewing the latest version or prospective version of legislation. They are therefore not accessible when viewing legislation as at a specific point in time. To view the ‘Changes to Legislation’ information for this provision return to the latest version view using the options provided in the ‘What Version’ box above.
27.—(1) Section 129(2A) of the 2006 Act (regulations as to pharmaceutical services) does not apply to an application—
(a)for temporary inclusion in a pharmaceutical list by a person not already included; or
(b)by a person already included in a pharmaceutical list for temporary inclusion in that list in respect of services, or services and premises, other than those already listed in relation to that person,
from a person (X) who proposes to provide pharmaceutical services which are not being provided because the person listed in relation to them (Y) is suspended from the pharmaceutical list.
(2) The NHSCB must refuse an application to which paragraph (1) applies—
(a)unless it is satisfied that—
(i)Y has nominated X as the person to provide those services for the duration of Y's suspension and consents to X doing so,
(ii)X will provide the same pharmaceutical services as those that Y provided or had undertaken to provide before the suspension, and
(iii)there is no direct or indirect connection between X and Y (including such a connection through a third party) the nature of which makes it unlikely that X will be able to exercise an appropriate degree of autonomy;
(b)if Y is a body corporate and X—
(i)is an employee of Y,
(ii)is, or was at the time of the suspension or of the originating events, a director or superintendent of Y,
(iii)is a body corporate in which Y or an employee of Y is a majority shareholder,
(iv)is a body corporate in which a majority shareholder of Y is, or was at the time of the suspension or of the originating events, a director or superintendent of X,
(v)is a body corporate which has a director or superintendent who is an employee of Y, or
(vi)is a body corporate which has as a director or superintendent someone who is, or was at the time of the suspension or of the originating events, a director or superintendent of Y;
(c)if Y is an individual and X—
(i)is an employee of Y,
(ii)is a body corporate of which Y or an employee of Y is a director or superintendent,
(iii)is a body corporate in which Y or an employee of Y is a majority shareholder, or
(iv)is a body corporate which has a director or superintendent who is an employee of Y; or
(d)if Y is a partnership and X—
(i)is or has been a member or employee of Y,
(ii)is a body corporate of which a member or employee of Y is or has been a director, superintendent or majority shareholder, or
(iii)is a partnership of which X, or a member or employee of X, is or has been a member.
(3) If an application to which—
(a)paragraph (1)(a) applies is granted, the applicant must only be included in the pharmaceutical list for a fixed period;
(b)paragraph (1)(b) applies is granted, the premises or services must only be listed in relation to the applicant for a fixed period.
(4) The fixed periods referred to in paragraph (3) must be no longer than—
(a)the period of Y's suspension; or
(b)until Y notifies the NHSCB, with effect from a specified date (which must be at least 2 working days after the date of the notification), that Y no longer consents to X providing the services that X is providing because of Y's suspension from the pharmaceutical list.
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: